- Home
- AXIN vs XOMA Comparison
AXIN vs XOMA Comparison
Compare AXIN & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXIN | XOMA |
|---|---|---|
| Founded | 2025 | 1981 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.8M | 308.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AXIN | XOMA |
|---|---|---|
| Price | $10.15 | $39.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | 16.8K | ★ 121.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.93 | $20.95 |
| 52 Week High | $10.19 | $40.25 |
Technical Indicators
Market Signals| Indicator | AXIN | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 83.56 |
| Support Level | $10.11 | $24.38 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.01 | 1.66 |
| MACD | 0.00 | 0.65 |
| Stochastic Oscillator | 33.33 | 90.39 |
Price Performance
Historical ComparisonAbout AXIN Axiom Intelligence Acquisition Corp 1 Class A Ordinary Shares
Axiom Intelligence Acquisition Corp 1 is a blank check company.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.